GLP-1 Market
LLY $1306.69 ▲ +2.8% NVO $39.43 ▲ +0.9% PFE $30.42 ▲ +1.9% VKTX $25.83 ▼ -2.1% KLRA $13.27 ▲ +2.7% GPCR $21.93 ▼ -0.4% RHHBY $59.62 ▲ +0.9%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

JR-141

JR-141

Company
JCR Pharmaceuticals Co., Ltd.
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Oct 23, 2026

Trial details
  • Completed NCT NCT03128593

    A Study of JR-141 in Patients With Mucopolysaccharidosis Type II

    Not yet reported, Not yet reported JCR Pharmaceuticals Co., Ltd. 14 participants Est. completion 2017-10-04 8 sites Stand-alone
    Other conditions: Mucopolysaccharidosis II
    View official trial listing →
  • Completed NCT NCT03359213

    A Study of JR-141 in Patients With Mucopolysaccharidosis II (BR21)

    Not yet reported JCR Pharmaceuticals Co., Ltd. 18 participants Est. completion 2019-10-04 2 sites Stand-alone
    Other conditions: Mucopolysaccharidosis II
    View official trial listing →
  • Completed NCT NCT03568175

    A Study of JR-141 in Patients With Mucopolysaccharidosis II

    Not yet reported, Not yet reported JCR Pharmaceuticals Co., Ltd. 28 participants Est. completion 2020-02-20 19 sites Stand-alone
    Other conditions: Mucopolysaccharidosis II
    View official trial listing →
  • Active, not recruiting NCT NCT03708965

    An Extension Study of JR-141-BR21 in Patients With Mucopolysaccharidosis II

    Not yet reported JCR Pharmaceuticals Co., Ltd. 19 participants Est. completion 2027-12-31 2 sites Stand-alone
    Other conditions: Mucopolysaccharidosis II
    View official trial listing →
  • Active, not recruiting NCT NCT04348136

    An Extension Study of JR-141 in Patients With Mucopolysaccharidosis Type II

    Not yet reported, Not yet reported JCR Pharmaceuticals Co., Ltd. 27 participants Est. completion 2030-03-31 20 sites Stand-alone
    Other conditions: Mucopolysaccharidosis II
    View official trial listing →
  • Active, not recruiting NCT NCT04573023

    A Phase III Study of JR-141 in Patients With Mucopolysaccharidosis II (STARLIGHT)

    Not yet reported JCR Pharmaceuticals Co., Ltd. 86 participants Est. completion 2027-10-31 26 sites Stand-alone
    Other conditions: Mucopolysaccharidosis II
    View official trial listing →
  • Enrolling by invitation NCT NCT05594992

    An Extension Study of JR-141 to Evaluate the Long-term Safety and Efficacy in MPS II (Hunter Syndrome) Subjects

    Not yet reported JCR Pharmaceuticals Co., Ltd. 80 participants Est. completion 2028-02-28 10 sites Stand-alone
    Other conditions: Mucopolysaccharidosis II
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.